The European Society of Cardiology Congress 2026 took place 28-31 August in Munich, Germany. Scientific presentations indicated a growing understanding of the use of SGLT2 inhibitors and the mineralocorticoid receptor antagonist finerenone for the treatment and management of heart failure. Image credit: [hydebrink]/Shutterstock.com. Image is from ESC 2018, which also took place in Munich.

Unlock FREE Access to Premium Content

​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.

With a free Pharmaceutical Technology profile, you can:

  • Access exclusive analyst commentary and expert insights
  • View premium forecasts and data-driven pharmaceutical industry insights
  • Stay up to date with pharma news, manufacturing innovation, and regulatory developments
  • Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here

Powered by